Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma
- Sponsor
- Flatiron Health
- Enrollment
- 1350
- Locations
- 2
- Primary Endpoint
- Blood and tissue biospecimen registry
- Status
- Recruiting
- Last Updated
- 8 months ago
Overview
Brief Summary
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back.
Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Blood and tissue biospecimen registry
Time Frame: Observation from enrollment to 5.5 years after enrollment
To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.